Related Experiment Video
Updated: Dec 28, 2025
06:20
Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor
Published on: January 12, 2024
2.5K
Gene expression profiling of primary vitreoretinal lymphoma
Ayako Arai1,2, Hiroshi Takase3, Mayumi Yoshimori1
1Department of Hematological Therapeutics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Cancer Science
|February 15, 2020
Summary
Primary vitreoretinal lymphoma (PVRL) exhibits unique genetic features, distinct from activated B-cell type diffuse large B-cell lymphoma (DLBCL). CD79B mutations may predict central nervous system progression in PVRL patients.
Area of Science:
- Ophthalmology
- Hematology
- Oncology
- Genetics
Background:
- Primary vitreoretinal lymphoma (PVRL) is a rare non-Hodgkin lymphoma.
- Most PVRL cases are classified as diffuse large B-cell lymphoma (DLBCL), but tumor cell characteristics remain undefined.
Purpose of the Study:
- To define the subtype and biological characteristics of tumor cells in PVRL.
- To investigate the genetic features and potential prognostic markers for PVRL.
Main Methods:
- Gene expression profiling of RNA from vitreous fluid of 7 PVRL patients.
- Comparison with gene expression profiles of nodal DLBCL (6 germinal center B-cell (GCB) type, 4 activated B-cell (ABC) type).
- Analysis of MYD88L265P and CD79B mutations; correlation with treatment response and central nervous system (CNS) progression.
Main Results:
- PVRL samples showed gene expression profiles distinct from ABC-type DLBCL but similar to GCB-type DLBCL.
- All examined PVRL samples harbored either MYD88L265P or CD79B ITAM mutations.
- CD79B mutations were associated with early CNS progression in patients treated with methotrexate (MTX).
Conclusions:
- PVRL possesses unique genetic features, with an expression pattern closer to GCB-type DLBCL than ABC-type DLBCL.
- CD79B mutations are potential prognostic markers for predicting CNS progression in PVRL.
